694 A randomized phase II clinical trial of SBRT and pembrolizumab with or without intratumoral avelumab/ipilimumab plus CD1c(BDCA-1)+/CD141(BDCA-3)+ myeloid dendritic cells in solid tumors

694 A randomized phase II clinical trial of SBRT and pembrolizumab with or without intratumoral avelumab/ipilimumab plus CD1c(BDCA-1)+/CD141(BDCA-3)+ myeloid dendritic cells in solid tumors

Bibliographic Details
Main Authors: Bart Neyns, Bart Ilsen, Jens Tijtgat, Frederik Vandenbroucke, Inès Dufait, Sandra Tuyaerts, Ivan Van Riet, Xenia Geeraerts, Latoya Stevens, Manon Vounckx, Iris Dirven, Steven Raemaeckers, Selma Ben Mustapha, Jens Van Loon, Lore Decoster, Mark De Ridder
Format: Article
Language:English
Published: BMJ Publishing Group 2023-11-01
Series:Journal for ImmunoTherapy of Cancer

Similar Items